Economically Motivated Adulteration: Food Fraud Hazards and Controls

Economically motivated adulteration is the intentional omission, removal or substitution of a valuable food ingredient or component, or the addition of a substance to make food appear better or more valuable. This follows the US FDA’s explanation of economically motivated adulteration, abbreviated here as EMA. Economic benefit is the distinguishing motivation: the alteration allows someone to obtain value that the food’s actual composition or quality does not justify.

This article focuses on food manufacturing: purchased ingredients, materials received at the site, and food produced for sale. For practical investigation, start with a specific claim about the material rather than a general suspicion about a supplier. Organise the inquiry around these questions:

• Declared ingredient: What identity, composition or quality was agreed in the specification and represented in the transaction?
• Suspected alteration: What might have been omitted, removed, substituted or added?
• Economic incentive: How could that alteration reduce cost, increase saleable quantity or support a higher selling price?
• Evidence needed: Which records, samples or analytical findings could distinguish the declared material from the suspected alternative?

Treat an authenticity discrepancy as a reason to investigate, not as proof of fraudulent intent. Keep the observed mismatch separate from the proposed explanation. This framing gives a food-fraud vulnerability assessment (see below) a concrete subject and helps teams using TACCP / VACCP describe what they are assessing before choosing controls.

In food-manufacturing investigations, EMA and food fraud are overlapping operational terms, not a universal hierarchy. As above, keep the suspected motivation separate from the food's condition: an economic motive does not by itself establish whether the food is safe.

For US human and animal food, FDA’s explanation of the FSMA distinction separates rules addressing economically motivated hazards from the intentional-adulteration rule addressing acts meant to cause wide-scale public-health harm. This is FDA’s explanation, not a substitute for the binding rule text.

Operational ownership commonly spans purchasing, food safety, quality and security. Route the investigation according to the evidence needed, not an assumed culprit. The department handling an incident neither proves intent nor determines legal liability.

For US human food subject to Part 117, 21 CFR 117.130(a)(1) requires a hazard analysis identifying and evaluating known or reasonably foreseeable hazards, based on experience, illness data, scientific reports and other information. Economic motivation is relevant to that analysis, but it does not by itself establish a food-safety hazard.

For US human food subject to Part 117, 21 CFR 117.130(b)(2)(iii) expressly includes: “The hazard may be intentionally introduced for purposes of economic gain.” The practical question is therefore not simply whether someone could profit from deception, but what harmful change that deception could introduce into the food.

Apply the safety boundary

For US human food subject to Part 117, 21 CFR 117.130(c)(1)(i) requires evaluation of the severity of illness or injury if the hazard occurs and its probability in the absence of preventive controls. For that same US human-food scope, 21 CFR 117.130(c)(2) states: “The hazard evaluation must consider the effect of the following on the safety of the finished food for the intended consumer:”

An economically motivated scenario belongs in this safety analysis where it may introduce a safety hazard. Commercial deception alone is not evidence of illness or injury. As an operational practice, describe the suspected alteration, identify the resulting hazard and explain the potential consumer harm before deciding how to address it. Keep commercial authenticity concerns visible without treating every authenticity failure as a preventive-control hazard.

For US human food subject to Part 117, 21 CFR 117.130(a)(2) requires the hazard analysis to be written regardless of its outcome. A practical record connects the scenario, supporting information, safety reasoning and conclusion, rather than recording only a fraud score.

FDA’s food-fraud explanation provides context. For framework terminology, see 21 CFR 117 and HARPC. For other jurisdictions and product categories, consult the current applicable rules rather than extending these provisions to them.

A food-fraud vulnerability assessment, sometimes described operationally as VACCP, is an industry-practice approach for identifying where economic incentives and opportunities for deception meet weak controls. Use it as a qualitative decision aid, not a prescribed regulatory procedure or a finding that a supplier has committed fraud.

Organise each assessment record around a specific material and supply route rather than assigning one judgement to an entire supplier:

• Material and claimed attribute: identify what is purchased and what could be misrepresented, such as identity, origin, purity or composition.
• Supplier or intermediary: distinguish the seller from the producer and identify uncertainty about who handles or transforms the material.
• Plausible fraud mechanism and economic incentive: describe the suspected substitution, dilution or concealment and how it could reduce cost or increase revenue.
• Detectability and existing evidence: record which checks could distinguish authentic from altered material, what they cannot distinguish, and which observations support the judgement.

Treat price or availability changes, opaque producer identity, unusual document changes and weak analytical discrimination as investigation prompts—not proof of fraud. For document concerns, a data integrity risk assessment can help focus questions about provenance and reliability.

Keep the vulnerability judgement separate from the safety-boundary assessment above: a plausible opportunity for deception does not itself demonstrate a safety hazard, and a low aggregate score should not dismiss a credible serious scenario. Record uncertainty, missing information and the evidence needed to resolve each open question explicitly.

Revisit the assessment when the producer changes, a specification changes, a result contradicts previous evidence or new fraud intelligence challenges an assumption. Assign an owner to each unresolved question; choose review timing to fit the material and circumstances rather than imposing a universal interval.

The following are recommended industry practices for food manufacturers, not an exhaustive statutory supplier programme. Select controls around the suspected alteration: who could introduce it, which purchased attribute it would change, and what evidence could expose it. Spend verification effort where the evidence can distinguish acceptable material from the suspected substitute or manipulation.

Distinguish the contractual supplier from the actual producer. Retain enough relationship information to identify the production site, intermediaries, and locations where material was repacked or relabelled. Link those relationships to the purchased material and lot. Treat an unexplained producer change as a reason for challenge, rather than assuming the distributor’s approval covers every source. Planned alternatives belong in dual-source qualification.

Define the identity being purchased in specifications: ingredient identity, declared origin, claimed grade and relevant composition. Identify how each attribute will be substantiated; do not assume a routine composition test establishes geographic origin or production history. Agree terminology with purchasing so that a commercially described equivalent does not silently replace the specified material.

Keep evidence roles separate. Supplier approval records the basis for accepting a source; a certificate of analysis (COA) reports stated results; incoming testing examines sampled material; a quality assurance audit examines selected practices and records. None substitutes for the others. Compare their findings and investigate contradictions rather than letting one favourable result override another concern.

As commercial and quality controls, agree purchasing change notification and access to underlying test information. Assign purchasing to obtain supplier explanations and quality personnel to assess their adequacy. Escalate unexplained substitutions, define who may challenge the supplier, and keep affected material from further use until discrepancies are resolved through an authorised human decision.

For supplement-ingredient purchasing, hypothetical vulnerabilities include substitution of a cheaper material for the specified ingredient, dilution with an undeclared carrier, and misleading documentation that describes a different material or lot. These are assessment scenarios, not claims about frequency. A useful purchasing question is whether the evidence distinguishes the ordered ingredient from the suspected substitute—not merely whether the paperwork looks complete.

For US dietary supplements, the supplier-certificate-of-analysis option in 21 CFR 111.75(a)(2)(ii) is conditional. Under that option, the following conditions apply:

• 21 CFR 111.75(a)(2)(ii)(A): first qualify the supplier by establishing COA reliability through confirmation of the supplier’s test or examination results.
• 21 CFR 111.75(a)(2)(ii)(B): the COA includes the methods used, test or examination limits, and actual results.
• 21 CFR 111.75(a)(2)(ii)(C): maintain documentation of how the supplier was qualified.
• 21 CFR 111.75(a)(2)(ii)(D): periodically reconfirm the supplier’s COA.
• 21 CFR 111.75(a)(2)(ii)(E): quality-control personnel review and approve the documented basis for supplier qualification and requalification.

Check the current product-specific text for the scope of COA reliance rather than treating this option as a universal substitute for incoming testing. Keep that scope check alongside the decision on component identity confirmation.

As an operational practice, a supplier COA verification programme can connect each suspected purchasing vulnerability to the evidence used to assess it. For example, if dilution is the concern, ask whether the reported test distinguishes diluted material from the specified ingredient. Keep the confirmation results and qualification rationale together so reviewers can see what supports reliance. A supplement supplier qualification audit can inform that assessment without being treated as proof that an individual lot is authentic.

These qualitative cases separate FDA-described events from hypothetical receiving-manufacturer responses. Assume purchases of olive oil for food production, finished infant formula for further packaging, and bulk grape juice for blending. No quantitative measurements, acceptance limits or calculated outcomes are assumed. The proposed responses illustrate food-fraud vulnerability assessment (see above), not the historical firms’ procedures.

Diluted oil: identity and safety are separate questions

FDA’s food-fraud explanation describes cheaper vegetable oil added to expensive olive oil and the mixture sold as pure olive oil.

Hypothetical response: the receiver holds the questioned lot while comparing its purchased identity with the label, specification and supplier composition records. An authenticity investigation would target substitution rather than simply repeat routine quality checks. Separately, the safety assessment would examine the particular substitute and whether it introduces a concern, such as an undeclared allergen; substitution alone does not identify that concern.

Unresolved question: what oil is actually present, and does it change the safety assessment? The next receiving decision needs lot-linked identity evidence, composition records and an assessment of the identified substitute.

False protein: a proxy can answer the wrong question

FDA’s infant-formula example explains that nitrogen can be used to estimate protein. It describes manufacturers in China adding nitrogen-rich melamine to make formula appear to contain enough protein and reports kidney failure in babies.

Hypothetical response: a receiver facing a credible melamine concern holds the affected stock and examines what the supplier’s protein result actually measures. Repeating a nitrogen-based estimate would not directly resolve suspected melamine addition. The investigation instead seeks evidence directed at melamine, alongside a separate assessment of the claimed protein content.

Unresolved question: is the apparent protein result misleading? The next decision needs representative lot-linked samples, an appropriate melamine-specific method and evidence supporting the nutritional claim—not merely another proxy result.

Concealed juice quality: reconstruct the blend

FDA’s concealed-quality example describes elevated arsenic and patulin findings and older grape juice blended with newer batches to hide poor quality.

Hypothetical response: the receiver holds the questioned delivery and traces contributing batches through supplier blending and storage records, linking them to its own electronic batch record. A supplier explanation that blending restored quality remains an explanation until supported by records and relevant contaminant evidence. Reviewing only the newest input would leave the older contributions unresolved.

Unresolved question: which inputs contributed to the delivery, and what safety concerns remain? The next decision needs reconciled batch genealogy, storage history and representative arsenic and patulin evidence for the implicated material, reviewed by the responsible quality personnel.

Start with the question: does the evidence address ingredient identity, composition, a particular contaminant or support for a declared attribute? In practical authenticity assessment, a pass answers only the question the method and acceptance criteria can resolve. It does not establish authenticity in every respect.

Use independent or complementary evidence, such as orthogonal identity testing, to challenge a specific substitution hypothesis—not to promise detection of every adulterant. Define what agreement, disagreement and an inconclusive result would mean before testing.

For raw-material sampling, consider where alteration could occur within the lot. Preserve sample identity and condition through collection and preparation. Interpret results within the method’s matrix coverage, selectivity and sensitivity; an undetected target does not prove its absence.

Use a coordinated investigation workflow for suspected food fraud. The following is recommended quality-governance practice, not a standalone regulatory procedure.

1. Register and assign. Record the concern, its origin, the suspected alteration and relevant supplier and lot identifiers. Name a quality investigation owner to coordinate supplier correspondence, laboratory work and decision deadlines.
2. Locate and contain. Receiving identifies stock locations and movement records; quality traces potentially affected material into production or shipments. Apply proportionate containment while identity or safety remains unresolved. A temporary material hold prevents unintended use; it is not a final finding of fraud.
3. Assess and collect. Food safety evaluates the plausible safety consequences and investigation scope. Purchasing obtains supplier explanations and supporting records. Laboratory personnel select suitable examinations, preserve sample chain of custody and report limitations alongside results.
4. Resolve discrepancies. The investigation owner compares purchasing records, receiving observations, supplier responses and laboratory findings. Assign each unresolved contradiction an action and owner rather than closing the investigation on a reassuring result alone.
5. Decide and learn. Keep acceptance, rejection, use restrictions and escalation decisions with authorised people through a documented quality disposition. Record the rationale, evidence considered, remaining uncertainty and conditions for subsequent action. Update the vulnerability assessment or supplier controls when findings change their underlying assumptions.

Treat software support as workflow assistance, not a product-release decision or proof of compliance. Human review and approval remain the decision point.

Use this proposed information design to connect food-fraud investigations across records. It is a vendor-neutral practice recommendation, not a prescribed regulatory database schema.

Optional connections among purchasing, receiving, laboratory and quality records can use these identifiers without replacing local systems. For laboratory integration, preserve specification and method versions, result units and document versions alongside each result.

Define exception recovery as an explicit reconciliation workflow:

• Unmatched lots: queue the record for receipt-to-lot reconciliation; do not guess the association.
• Missing units: request clarification from the originating laboratory rather than infer units from a specification.
• Duplicate uploads: flag potential duplicates and retain upload history while confirming whether the contents differ.
• Changed supplier identifiers: maintain a reviewed cross-reference between old and new identifiers.
• Conflicting document versions: preserve both and route the conflict to an assigned reconciliation owner.

Keep unresolved records visible rather than silently overwriting or discarding them. Make corrections attributable: record who changed what, when and why; link each correction to its original document. Retain superseded evidence and its relationship to the decision that relied on it, supporting audit-trail review. Use the disposition authority described in the preceding section.

Complete, well-linked records improve reviewability; they do not establish ingredient authenticity.

Use this practical self-assessment at the receiving or use decision—not as certification or proof of authenticity.

• Responsibility: confirm the investigation lead, assessment owner and disposition authority named under the lifecycle above are still correct for this material.
• Producer access: confirm purchasing can retrieve producer identity and supporting information through the supply chain.
• Purchased attributes: check that specifications identify the attributes whose authenticity matters to the decision.
• Relevant evidence: ask whether laboratory conclusions answer the original investigation question, including method limitations.
• Lot traceability: demonstrate links from the ingredient receipt to affected stock and production batches.
• Disposition: record the evidence, remaining uncertainty and rationale for the authorised decision.
• Open exceptions: keep unresolved record failures visible in exception-based review, and confirm supplier changes reach the assessment owner.

Run a tabletop review: select an ingredient, follow purchase through receiving and use, then introduce a realistic authenticity concern. Can the team retrieve enough evidence to resolve it? Assign each finding to the relevant control and an effectiveness check, rather than adding documents without a decision purpose.

Apply these principles in the FAQs to broker documentation, sparse ingredient history, price changes, origin claims, brand-owner evidence, conflicting laboratories, in-process material and corrected certificates.